L. Majorité-des-patients-avaient-un and O. , 72%, 11 données manquantes) La proportion de patients avec un OMS 3 était largement minoritaire, p.1

R. Lepage, C. Bouvier, A. Phelip, and J. , Incidence and management of malignant digestive endocrine tumours in a well defined French population, Gut, vol.53, issue.4, pp.549-553, 2004.
DOI : 10.1136/gut.2003.026401

T. Walter, J. Scoazec, and C. Lepage, Epidemiologie des tumeurs neuroendocrines digestives : la situation en france, Hepato Gastro, vol.20, pp.160-166, 2013.

C. Lombard-bohas, E. Mitry, and D. O-'toole, Thirteen-Month Registration of Patients with Gastroenteropancreatic Endocrine Tumours in France, Neuroendocrinology, vol.89, issue.2, pp.217-222, 2009.
DOI : 10.1159/000151562

P. Leotlela, A. Jauch, and H. Holtgreve-grez, Genetics of neuroendocrine and carcinoid tumours, Endocrine Related Cancer, vol.10, issue.4, pp.437-450, 2003.
DOI : 10.1677/erc.0.0100437

I. Modlin, K. Oberg, and D. Chung, Gastropancreatic neuroendocrine tumours, Lancet Oncol, issue.9, pp.61-72, 2008.

A. Pearse, The apud cell concept and its implications in pathology, Pathol Annu, issue.9, pp.27-41, 1974.

C. Capella, P. Heitz, and H. Hofler, Revised classification of neuroendocrine tumours of the lung, pancreas and gut, Virchows Archiv, vol.425, issue.6, pp.547-560, 1995.
DOI : 10.1007/BF00199342

J. Scoazec and A. Couvelard, Tumeurs neuroendocrines du tube digestif et du pancr??as??: ce que le pathologiste doit savoir et doit faire en 2014, Annales de Pathologie, vol.34, issue.1, pp.40-50, 2014.
DOI : 10.1016/j.annpat.2014.01.003

E. Williams and M. Sandler, THE CLASSIFICATION OF CARCINOID TUMOURS, The Lancet, vol.281, issue.7275, pp.238-239, 1963.
DOI : 10.1016/S0140-6736(63)90951-6

T. Bosman, F. Carneiro, R. Hruban, and N. Theise, Who classification of tumours of the digestive system, International Agency for Research on Cancer (IARC), 2010.

O. Basturk, L. Tang, and R. Hruban, Poorly Differentiated Neuroendocrine Carcinomas of the Pancreas, The American Journal of Surgical Pathology, vol.38, issue.4, pp.437-447
DOI : 10.1097/PAS.0000000000000169

F. Velayoudom-céphise, P. Duvillard, and L. Foucan, Are G3 ENETS neuroendocrine neoplasms heterogeneous?, Endocrine Related Cancer, vol.20, issue.5, pp.649-657, 2013.
DOI : 10.1530/ERC-13-0027

M. Voss, P. Hammel, and G. Molas, Value of endoscopic ultrasound guided fine needle aspiration biopsy in the diagnosis of solid pancreatic masses, Gut, vol.46, issue.2, pp.244-249, 2000.
DOI : 10.1136/gut.46.2.244

E. Solcia, G. Kloppel, and L. Sobin, Histological typing of endocrine tumours. International Histological Classification of Tumours, pp.61-68, 2000.

G. Rindi, G. Kloppel, and H. Alhman, TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system, Virchows Archiv, vol.80, issue.Suppl 4, pp.395-401, 2006.
DOI : 10.1007/s00428-006-0250-1

G. Rindi, G. Kloppel, and A. Couvelard, TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system, Virchows Archiv, vol.80, issue.Suppl 4, pp.757-762, 2007.
DOI : 10.1007/s00428-007-0452-1

L. Sobin and . Wittekind, Tnm classification of malignant tumours, 2009.
DOI : 10.1002/0471463752

G. Rindi, M. Falconi, and C. Klersy, TNM Staging of Neoplasms of the Endocrine Pancreas: Results From a Large International Cohort Study, JNCI Journal of the National Cancer Institute, vol.104, issue.10, pp.764-777, 2012.
DOI : 10.1093/jnci/djs208

J. Strosberg, J. Weber, and M. Feldman, Prognostic Validity of the American Joint Committee on Cancer Staging Classification for Midgut Neuroendocrine Tumors, Journal of Clinical Oncology, vol.31, issue.4, pp.420-425, 2013.
DOI : 10.1200/JCO.2012.44.5924

M. Falconi, D. Bartsch, and B. Eriksson, ENETS Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Neoplasms of the Digestive System: Well-Differentiated Pancreatic Non-Functioning Tumors, Neuroendocrinology, vol.95, issue.2, pp.120-134, 2012.
DOI : 10.1159/000335587

R. Bettini, S. Partelli, and L. Boninsegna, Tumor size correlates with malignancy in nonfunctioning pancreatic endocrine tumor, Surgery, vol.150, issue.1, pp.75-82, 2011.
DOI : 10.1016/j.surg.2011.02.022

S. Partelli, A. Maurizi, and D. Tamburrino, GEP-NETS UPDATE: A review on surgery of gastro-entero-pancreatic neuroendocrine tumors, European Journal of Endocrinology, vol.171, issue.4, pp.153-162, 2014.
DOI : 10.1530/EJE-14-0173

G. Bommelaer, Treatment of carcinoid syndrome : a prospective crossover evaluation of lanreotide versus octrotide in terms of efficacy, patient acceptability, and tolerance, Cancer, vol.88, pp.770-776, 2000.

A. Rinke, H. Müller, and C. Schade-brittinger, Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group, Journal of Clinical Oncology, vol.27, issue.28
DOI : 10.1200/JCO.2009.22.8510

M. Caplin, M. Pavel, and P. Ruszniewski, Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors, New England Journal of Medicine, vol.371, issue.3, pp.224-233, 2014.
DOI : 10.1056/NEJMoa1316158

C. Moertel, L. O. Kvols, and M. Connell, Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms, Cancer, vol.109, issue.2, pp.227-232, 1991.
DOI : 10.1002/1097-0142(19910715)68:2<227::AID-CNCR2820680202>3.0.CO;2-I

H. Sorbye, S. Welin, and S. Langer, Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study, Annals of Oncology, vol.24, issue.1, pp.152-160, 2013.
DOI : 10.1093/annonc/mds276

P. Hammel, O. Hentic, and C. Neuzillet, New treatment options with cytotoxic agents in neuroendocrine tumours, Targeted Oncology, vol.117, issue.16S, pp.169-72, 2012.
DOI : 10.1007/s11523-012-0228-7

H. Matthew, L. Jason, C. Hornick, and . Frauenhoffer, O6-methylguanine dna methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors, Clin Cancer Res, vol.15, pp.338-345, 2009.

J. Yao, M. Shah, and T. Ito, Everolimus for Advanced Pancreatic Neuroendocrine Tumors, New England Journal of Medicine, vol.364, issue.6, pp.514-523, 2011.
DOI : 10.1056/NEJMoa1009290

E. Raymond, L. Dahan, and J. Raoul, Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors, New England Journal of Medicine, vol.364, issue.6, pp.501-513, 2011.
DOI : 10.1056/NEJMoa1003825

F. Maire, C. Lombard-bohas, and D. O-'toole, Hepatic Arterial Embolization versus Chemoembolization in the Treatment of Liver Metastases from Well-Differentiated Midgut Endocrine Tumors: A Prospective Randomized Study, Neuroendocrinology, vol.96, issue.4, pp.294-300, 2012.
DOI : 10.1159/000336941

M. Pavel, E. Baudin, and A. Couvelard, ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary, Neuroendocrinology, vol.95, issue.2, pp.157-176, 2012.
DOI : 10.1159/000335597

J. Scoazec, G. Monges, and E. Leteurtre, Tumeurs neuroendocrines digestives de grade 3 bien differenciees : mythe ou realite ? etude pronet, 2013.

F. Borson-chazot, C. Lombard-bohas, and P. Ruszniewski, Clinical characteristics of the 5 160 patients included in the french database of the french endocrine tumor group (gte), ENETS Lisbon, 2011.

C. Lepage, V. Cottet, and A. Bouvier, Epidemiologie des tumeurs endocrines digestives. Hepato- Gastro, pp.5-8, 2009.

C. Lepage, B. Rachet, and M. Coleman, Survival From Malignant Digestive Endocrine Tumors in England and Wales: A Population-Based Study, Gastroenterology, vol.132, issue.3, pp.899-904, 2007.
DOI : 10.1053/j.gastro.2007.01.006

M. Niederle, M. Hackl, and K. Kaserer, Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters, Endocrine Related Cancer, vol.17, issue.4, pp.909-918, 2010.
DOI : 10.1677/ERC-10-0152

J. Yao, M. Hassan, and A. Phan, One Hundred Years After ???Carcinoid???: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States, Journal of Clinical Oncology, vol.26, issue.18, pp.3063-3072, 2008.
DOI : 10.1200/JCO.2007.15.4377

H. Scherübl, B. Streller, and R. Stabenow, Clinically detected gastroenteropancreatic neuroendocrine tumors are on the rise: Epidemiological changes in Germany, World Journal of Gastroenterology, vol.19, issue.47, pp.9012-9019, 2013.
DOI : 10.3748/wjg.v19.i47.9012

C. Lepage, L. Ciccolallo, and R. De-angelis, European disparities in malignant digestive endocrine tumours survival, International Journal of Cancer, vol.14, pp.2928-2934, 2010.
DOI : 10.1002/ijc.24698

L. Sobin and I. Fleming, Tnm classification of malignant tumors, fifth edition. Union Internationale Contre le Cancer and the American Joint Committee on Cancer, pp.1803-1804, 1997.

L. Yu, C. Lv, and A. Yuan, Significance of the preoperative neutrophil-to-lymphocyte ratio in the prognosis of patients with gastric cancer, World Journal of Gastroenterology, vol.21, issue.20, pp.6280-6286, 2015.
DOI : 10.3748/wjg.v21.i20.6280

J. Feng, Y. Huang, and Q. Chen, Preoperative platelet lymphocyte ratio (PLR) is superior to neutrophil lymphocyte ratio (NLR) as a predictive factor in patients with esophageal squamous cell carcinoma, World Journal of Surgical Oncology, vol.12, issue.1, p.58, 2014.
DOI : 10.1007/s00268-011-1130-7

M. Fraenkel, M. Kim, and A. Faggiano, Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature, Endocrine Related Cancer, vol.21, issue.3, pp.153-163, 2014.
DOI : 10.1530/ERC-13-0125

R. Garcia-carbonero, J. Capdevila, and G. Crespo-herrero, Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE), Annals of Oncology, vol.21, issue.9, pp.1794-1803, 2010.
DOI : 10.1093/annonc/mdq022

R. Abgral, S. Leboulleux, and D. Déandreis, Fluorodeoxyglucose-Positron Emission Tomography and Somatostatin Receptor Scintigraphy for High Ki67 (???10%) Well-Differentiated Endocrine Carcinoma Staging, The Journal of Clinical Endocrinology & Metabolism, vol.96, issue.3, pp.665-671, 2011.
DOI : 10.1210/jc.2010-2022

E. Garin, F. Le-jeune, and A. Devillers, Predictive Value of 18F-FDG PET and Somatostatin Receptor Scintigraphy in Patients with Metastatic Endocrine Tumors, Journal of Nuclear Medicine, vol.50, issue.6, pp.858-864, 2009.
DOI : 10.2967/jnumed.108.057505